BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
22/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBCLI / S&P 5.26% / 15.20% |
LoseBCLI / S&P BCLI unavailable / 15.00% |
LoseBCLI / S&P -48.62% / 50.40% |
| 2026-Q11/3 |
WinBCLI / S&P 72.73% / -4.33% |
LoseBCLI / S&P BCLI unavailable / 11.30% |
LoseBCLI / S&P -55.56% / 27.70% |
| 2025-Q40/3 |
LoseBCLI / S&P -22.54% / 2.65% |
LoseBCLI / S&P BCLI unavailable / 9.00% |
LoseBCLI / S&P -50.21% / 13.40% |
| 2025-Q30/3 |
LoseBCLI / S&P -36.61% / 8.12% |
LoseBCLI / S&P BCLI unavailable / 4.61% |
LoseBCLI / S&P -57.55% / 13.45% |
| 2025-Q20/3 |
LoseBCLI / S&P -11.11% / 10.94% |
LoseBCLI / S&P BCLI unavailable / 4.83% |
LoseBCLI / S&P -47.54% / 10.63% |
| 2025-Q10/3 |
LoseBCLI / S&P -44.49% / -4.27% |
LoseBCLI / S&P BCLI unavailable / 4.98% |
LoseBCLI / S&P -30.54% / 10.57% |
| 2024-Q40/3 |
LoseBCLI / S&P -34.20% / 2.41% |
LoseBCLI / S&P BCLI unavailable / 5.25% |
LoseBCLI / S&P 0.00% / 6.15% |
| 2024-Q31/3 |
LoseBCLI / S&P -32.35% / 5.89% |
LoseBCLI / S&P BCLI unavailable / 5.89% |
WinBCLI / S&P 312.94% / 6.11% |
| 2024-Q21/3 |
LoseBCLI / S&P -39.29% / 4.28% |
LoseBCLI / S&P BCLI unavailable / 5.38% |
WinBCLI / S&P 484.75% / 5.12% |
| 2024-Q12/3 |
WinBCLI / S&P 107.41% / 10.56% |
LoseBCLI / S&P BCLI unavailable / 5.71% |
WinBCLI / S&P 358.46% / 5.59% |
| 2023-Q42/3 |
WinBCLI / S&P 35.00% / 11.69% |
LoseBCLI / S&P BCLI unavailable / 6.81% |
WinBCLI / S&P 259.09% / 7.78% |
| 2023-Q31/3 |
LoseBCLI / S&P -90.29% / -3.27% |
LoseBCLI / S&P BCLI unavailable / 7.52% |
WinBCLI / S&P 21.43% / -5.03% |
| 2023-Q20/3 |
LoseBCLI / S&P -37.58% / 8.74% |
LoseBCLI / S&P BCLI unavailable / 9.50% |
LoseBCLI / S&P -10.61% / -8.57% |
| 2023-Q12/3 |
WinBCLI / S&P 101.22% / 7.50% |
LoseBCLI / S&P BCLI unavailable / 10.77% |
WinBCLI / S&P 1.56% / -15.69% |
| 2022-Q41/3 |
LoseBCLI / S&P -62.90% / 7.56% |
LoseBCLI / S&P BCLI unavailable / 11.88% |
WinBCLI / S&P -2.94% / -17.99% |
| 2022-Q31/3 |
WinBCLI / S&P 60.14% / -4.88% |
LoseBCLI / S&P BCLI unavailable / 13.47% |
LoseBCLI / S&P BCLI unavailable / -1.41% |
| 2022-Q20/3 |
LoseBCLI / S&P -17.86% / -16.10% |
LoseBCLI / S&P BCLI unavailable / 13.71% |
LoseBCLI / S&P BCLI unavailable / 11.04% |
| 2022-Q10/3 |
LoseBCLI / S&P -16.00% / -4.60% |
LoseBCLI / S&P BCLI unavailable / 15.97% |
LoseBCLI / S&P BCLI unavailable / 42.23% |
| 2021-Q41/3 |
WinBCLI / S&P 21.21% / 11.03% |
LoseBCLI / S&P BCLI unavailable / 15.00% |
LoseBCLI / S&P BCLI unavailable / 96.40% |
| 2021-Q30/3 |
LoseBCLI / S&P -13.16% / 0.58% |
LoseBCLI / S&P BCLI unavailable / 10.77% |
LoseBCLI / S&P BCLI unavailable / 69.42% |
| 2021-Q20/3 |
LoseBCLI / S&P -0.78% / 8.55% |
LoseBCLI / S&P BCLI unavailable / 6.58% |
LoseBCLI / S&P BCLI unavailable / 51.81% |
| 2021-Q10/3 |
LoseBCLI / S&P -15.45% / 6.17% |
LoseBCLI / S&P BCLI unavailable / -1.06% |
LoseBCLI / S&P BCLI unavailable / 7.39% |
| 2020-Q40/3 |
LoseBCLI / S&P -73.23% / 12.15% |
LoseBCLI / S&P BCLI unavailable / -3.72% |
LoseBCLI / S&P BCLI unavailable / -33.42% |
| 2020-Q31/3 |
WinBCLI / S&P 50.94% / 8.93% |
LoseBCLI / S&P BCLI unavailable / -2.04% |
LoseBCLI / S&P BCLI unavailable / -27.10% |
| 2020-Q21/3 |
WinBCLI / S&P 141.59% / 20.54% |
LoseBCLI / S&P BCLI unavailable / -0.46% |
LoseBCLI / S&P BCLI unavailable / -27.11% |
| 2020-Q11/3 |
WinBCLI / S&P 8.41% / -19.60% |
LoseBCLI / S&P BCLI unavailable / 3.47% |
LoseBCLI / S&P BCLI unavailable / -14.75% |
| 2019-Q41/3 |
WinBCLI / S&P 9.74% / 9.07% |
LoseBCLI / S&P BCLI unavailable / 5.36% |
LoseBCLI / S&P BCLI unavailable / 2.99% |
| 2019-Q30/3 |
LoseBCLI / S&P -1.27% / 1.70% |
LoseBCLI / S&P BCLI unavailable / 5.02% |
LoseBCLI / S&P BCLI unavailable / 0.21% |
| 2019-Q20/3 |
LoseBCLI / S&P -8.99% / 4.30% |
LoseBCLI / S&P BCLI unavailable / 6.64% |
LoseBCLI / S&P BCLI unavailable / 8.65% |
| 2019-Q11/3 |
WinBCLI / S&P 22.25% / 13.65% |
LoseBCLI / S&P BCLI unavailable / 8.12% |
LoseBCLI / S&P BCLI unavailable / 14.29% |
| 2018-Q41/3 |
WinBCLI / S&P -7.07% / -13.52% |
LoseBCLI / S&P BCLI unavailable / 9.05% |
LoseBCLI / S&P BCLI unavailable / 18.23% |
| 2018-Q30/3 |
LoseBCLI / S&P -2.05% / 7.71% |
LoseBCLI / S&P BCLI unavailable / 10.21% |
LoseBCLI / S&P BCLI unavailable / 19.06% |
| 2018-Q21/3 |
WinBCLI / S&P 23.81% / 3.43% |
LoseBCLI / S&P BCLI unavailable / 9.03% |
LoseBCLI / S&P BCLI unavailable / 14.46% |
| 2018-Q10/3 |
LoseBCLI / S&P -19.64% / -0.76% |
LoseBCLI / S&P BCLI unavailable / 7.68% |
LoseBCLI / S&P BCLI unavailable / 12.46% |
| 2017-Q40/3 |
LoseBCLI / S&P -4.85% / 6.64% |
LoseBCLI / S&P BCLI unavailable / 7.03% |
LoseBCLI / S&P BCLI unavailable / 13.82% |
| 2017-Q30/3 |
LoseBCLI / S&P -0.72% / 4.48% |
LoseBCLI / S&P BCLI unavailable / 5.68% |
LoseBCLI / S&P BCLI unavailable / 17.57% |
| 2017-Q20/3 |
LoseBCLI / S&P -2.35% / 3.09% |
LoseBCLI / S&P BCLI unavailable / 4.83% |
LoseBCLI / S&P BCLI unavailable / 17.74% |
| 2017-Q11/3 |
WinBCLI / S&P 67.32% / 6.07% |
LoseBCLI / S&P BCLI unavailable / 3.67% |
LoseBCLI / S&P BCLI unavailable / 13.32% |
| 2016-Q41/3 |
WinBCLI / S&P 5.39% / 3.82% |
LoseBCLI / S&P BCLI unavailable / 2.09% |
LoseBCLI / S&P BCLI unavailable / 7.05% |
| 2016-Q30/3 |
LoseBCLI / S&P 0.00% / 3.85% |
LoseBCLI / S&P BCLI unavailable / 0.20% |
LoseBCLI / S&P BCLI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BCLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 52.63% | 20.78% |
| Annualized return | 52.63% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | BCLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.82% | 83.14% |
| Annualized return | -53.48% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | BCLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.82% | 319.30% |
| Annualized return | -29.16% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |